• Something wrong with this record ?

Hydrazones of 4-(Trifluoromethyl)benzohydrazide as New Inhibitors of Acetyl- and Butyrylcholinesterase

M. Krátký, K. Svrčková, QA. Vu, Š. Štěpánková, J. Vinšová

. 2021 ; 26 (4) : . [pub] 20210213

Language English Country Switzerland

Document type Journal Article

Grant support
20-19638Y Grantová Agentura České Republiky
No. CZ.02.1.01/0.0/0.0/16_019/0000841 European Regional Development Fund

Based on the broad spectrum of biological activity of hydrazide-hydrazones, trifluoromethyl compounds, and clinical usage of cholinesterase inhibitors, we investigated hydrazones obtained from 4-(trifluoromethyl)benzohydrazide and various benzaldehydes or aliphatic ketones as potential inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). They were evaluated using Ellman's spectrophotometric method. The hydrazide-hydrazones produced a dual inhibition of both cholinesterase enzymes with IC50 values of 46.8-137.7 µM and 19.1-881.1 µM for AChE and BuChE, respectively. The majority of the compounds were stronger inhibitors of AChE; four of them (2-bromobenzaldehyde, 3-(trifluoromethyl)benzaldehyde, cyclohexanone, and camphor-based 2o, 2p, 3c, and 3d, respectively) produced a balanced inhibition of the enzymes and only 2-chloro/trifluoromethyl benzylidene derivatives 2d and 2q were found to be more potent inhibitors of BuChE. 4-(Trifluoromethyl)-N'-[4-(trifluoromethyl)benzylidene]benzohydrazide 2l produced the strongest inhibition of AChE via mixed-type inhibition determined experimentally. Structure-activity relationships were identified. The compounds fit physicochemical space for targeting central nervous systems with no apparent cytotoxicity for eukaryotic cell line together. The study provides new insights into this CF3-hydrazide-hydrazone scaffold.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019251
003      
CZ-PrNML
005      
20210830100830.0
007      
ta
008      
210728s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/molecules26040989 $2 doi
035    __
$a (PubMed)33668452
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Krátký, Martin $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
245    10
$a Hydrazones of 4-(Trifluoromethyl)benzohydrazide as New Inhibitors of Acetyl- and Butyrylcholinesterase / $c M. Krátký, K. Svrčková, QA. Vu, Š. Štěpánková, J. Vinšová
520    9_
$a Based on the broad spectrum of biological activity of hydrazide-hydrazones, trifluoromethyl compounds, and clinical usage of cholinesterase inhibitors, we investigated hydrazones obtained from 4-(trifluoromethyl)benzohydrazide and various benzaldehydes or aliphatic ketones as potential inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). They were evaluated using Ellman's spectrophotometric method. The hydrazide-hydrazones produced a dual inhibition of both cholinesterase enzymes with IC50 values of 46.8-137.7 µM and 19.1-881.1 µM for AChE and BuChE, respectively. The majority of the compounds were stronger inhibitors of AChE; four of them (2-bromobenzaldehyde, 3-(trifluoromethyl)benzaldehyde, cyclohexanone, and camphor-based 2o, 2p, 3c, and 3d, respectively) produced a balanced inhibition of the enzymes and only 2-chloro/trifluoromethyl benzylidene derivatives 2d and 2q were found to be more potent inhibitors of BuChE. 4-(Trifluoromethyl)-N'-[4-(trifluoromethyl)benzylidene]benzohydrazide 2l produced the strongest inhibition of AChE via mixed-type inhibition determined experimentally. Structure-activity relationships were identified. The compounds fit physicochemical space for targeting central nervous systems with no apparent cytotoxicity for eukaryotic cell line together. The study provides new insights into this CF3-hydrazide-hydrazone scaffold.
650    _2
$a acetylcholinesterasa $x metabolismus $7 D000110
650    _2
$a hematoencefalická bariéra $x účinky léků $x patologie $7 D001812
650    _2
$a butyrylcholinesterasa $x metabolismus $7 D002091
650    _2
$a centrální nervový systém $x účinky léků $7 D002490
650    _2
$a cholinesterasové inhibitory $x farmakologie $7 D002800
650    _2
$a lidé $7 D006801
650    _2
$a hydraziny $x chemie $7 D006834
650    _2
$a hydrazony $x chemie $x farmakologie $7 D006835
650    _2
$a kinetika $7 D007700
655    _2
$a časopisecké články $7 D016428
700    1_
$a Svrčková, Katarína $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 532 10 Pardubice, Czech Republic
700    1_
$a Vu, Quynh Anh $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
700    1_
$a Štěpánková, Šárka $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 532 10 Pardubice, Czech Republic
700    1_
$a Vinšová, Jarmila $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
773    0_
$w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 26, č. 4 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33668452 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100830 $b ABA008
999    __
$a ok $b bmc $g 1690145 $s 1139697
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 26 $c 4 $e 20210213 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
GRA    __
$a 20-19638Y $p Grantová Agentura České Republiky
GRA    __
$a No. CZ.02.1.01/0.0/0.0/16_019/0000841 $p European Regional Development Fund
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...